Nymox Pharmaceutical Corp (NYMX)

TSIF (98.75) Submitted: 8/27/2009 1:49:19 PM : Start Price: $6.60 NYMX Score: -39.59

Occasionally, while trying to net some points on CAPs, I let the 20 minute wait rule on CAPs get me rattled. I open and close my down thrumbs several times trying to time a peak. Several times now, in my haste, I've let the stock pick activate after opening and cancelling it a few times, and not changing the pick to down on the last cycle, leaving me in the WRONG direction. Most pharaceuticals, in early trials will get some positive news that drives the speculators, looking for a Dendron or HGSI type gain. Typically the buy on the news is overdone and profit takers get a few cycles. These are often promising companies, but from the CAPs perspective of "short run" they aren't likely to pan out until the FDA gets it's day. I do like Nymox's chances, and I have friends suffering from Liver Cancer. In the long run, I might be a buyer, possibley even at todays $4.75 price. The $7.07 this spiked to, just a few days ago when I attempted to swing trade it on caps and wrong way'd it, was clearly a market "over" reaction. Like my green thumb, those buying at $7.07 will come out ahead, if they hold, and Nymox progresses further into the FDA cycle. If proven safe and effective, then those willing to incur the risk by getting in early stand the most to gain. Best of luck to Nymox long holders. I expect to turn this pick green in the future, but lower starting price would have been nicer! Swing trading is best done by those with more time to "play" and better attention spans, (real time opening and closing bids would help)!

mepedrou (< 20) Submitted: 1/8/2009 2:28:58 PM : Start Price: $3.55 NYMX Score: +2.25

nx 1207 drug a guaranteed winner

GershwinStephen (< 20) Submitted: 1/30/2008 5:33:55 PM : Start Price: $5.07 NYMX Score: +2.53

acquisiton,

NeroSagetrade (90.56) Submitted: 10/11/2007 6:53:50 PM : Start Price: $6.25 NYMX Score: +2.42

There are far too many of these types of pharmaceutical companies out there...plenty of promise, huge valuation and failure to deliver. Nymox currently has one...yes..only one drug currently in late stage trials to treat enlarging prostates. The company has managed just 450k in sales for the entire year yet is valued at over 183 million dollars. Losses are increasing, and based on my estimates, they dont even have enough cash to get out of Q1 2008! Over 400 times price to sales, 58 times book, and increasing losses..where's the buy button?!! If you look historically at the long-term chart, this falls mercilessly for 2-3 months after every large rise.

Nero

Sagetrade

Voyt608 (72.10) Submitted: 4/12/2007 9:07:23 AM : Start Price: $5.61 NYMX Score: -0.99

Non estrogenic treatment for benign proatatic hyperplasia with proven efficacy ih reducing symptoms such as frepuent voiding, urgency, nocturia, dripping etc. No significant side effects and a 30% reduction in prostate size in late trials. Tremendous market potential.

NetscribeHealthC (< 20) Submitted: 3/23/2007 9:26:46 AM : Start Price: $5.95 NYMX Score: +5.88

Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company that owns and operates business through two subsidiaries: Nymox Corporation, a wholly owned subsidiary and Serex, Inc., a majority owned subsidiary. The company has three products in its portfolio; AlzheimAlert meant to measure the level of a brain protein, NicAlert to determine smoking status and TobacAlert determination of a person’s level of exposure to tobacco products including second hand smoke.

The company is pursuing research and development pipeline of drug and diagnostic products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer's disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications.

Nymox’s financial statements indicate that it is still very much in its development phase. For the fiscal 2006 its revenues were mere $0.44 million whereas it reported net loss of $4.89 million which was 63% more than the previous year.

The driver for this stock would be its Phase II product candidate NX-1207 which is meant to treat BPH. The stocked reacted positively on the recent announcement of positive test data.

The company’s valuation looks expensive especially if one takes into account its $ 44 million deficit and that it is going to take few years for it to generate positive free cash flows. Thus in today’s environment where risk aversion is the norm this stock doesn’t make the grade. Hence its better to be prudent while thinking of investing in the stock.

peddishiva (< 20) Submitted: 2/22/2007 12:45:20 AM : Start Price: $6.00 NYMX Score: -5.28

Nymox has an extensive pipeline of products under development, including therapeutics for enlarged prostate (BPH), a common affliction of males over the age of 50, and for Alzheimer's disease, the most common cause of dementia in the elderly.

fiona53 (< 20) Submitted: 2/18/2007 4:03:24 AM : Start Price: $5.70 NYMX Score: -1.57

very interesting pipeline

bdylan (< 20) Submitted: 2/8/2007 9:26:10 PM : Start Price: $5.25 NYMX Score: +4.98

Nymox has intellectual patented technology worldwide with statin gene marker for alzheimers disease.
Their drug for shrinking prostate gland that has enlarged has no known high risk side effects. Their research on eliminating the ecoli bacteria in food is moving forward . I bleive this company is positioned for solid growth thru revenues and earnings generated by these proprietory techniques and the royalties generated by these products :leased: to other major pharmaceutical companies should enhance earnings and price..